Page 1

Table of Contents ( Mark One ) ☑ ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , DC 20549 Form 10 - K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Delaware Commission file number 001-37809 NeuroBo Pharmaceuticals , Inc. ( Exact name of Registrant as specified in its charter ) ( State or other jurisdiction of incorporation or organization ) 200 Berkeley Street , Office 19th Floor Boston , Massachusetts ( Address of principal executive offices ) 47-2389984 ( IRS Employer Identification No. ) 02116 ( Zip Code ) ( 857 ) 702-9600 ( Registrant's telephone number , including area code ) Securities registered pursuant to Section 12 ( b ) of the Securities Exchange Act of 1934 : Title of Each Class Common stock , $ 0.001 par value Trading symbol ( s ) NRBO Name of Exchange on Which Registered The Nasdaq Stock Market LLC Securities registered pursuant to Section 12 ( g ) of the Act : None Indicate by check mark whether the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . Yes □ No Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes No □ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( $ 232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes No □ Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , a smaller reporting company , or an emerging growth company . See the definitions of " large accelerated filer , " " accelerated filer , " " smaller reporting company , " and " emerging growth company " in Rule 12b - 2 of the Exchange Act . Large accelerated filer ☐ Accelerated filer Smaller reporting company ☑ Non - accelerated filer Emerging growth company If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404 ( b ) of the Sarbanes - Oxley Act ( 15 U.S.C. 7262 ( b ) ) by the registered public accounting firm that prepared or issued its audit report . Yes No Indicate by check mark whether the registrant is a shell company ( as defined in Rule 12 ( b ) -2 of the Securities Exchange Act of 1934 ) . Yes □ No ☑ The aggregate market value of the registrant's common stock held non - affiliates of the registrant was approximately $ 23.4 million based on the closing price on the Nasdaq Capital Market as of June 28 , 2020 , the last business day of the registrant's most recently completed second fiscal quarter . The number of outstanding shares of the registrant's common stock , $ 0.001 par value , as of April 9 , 2021 was 22,171,182 .